Severe Obesity in Children and Adolescents: Identification, Associated Health Risks, and Treatment Approaches A Scientific Statement From the American Heart Association

被引:742
作者
Kelly, Aaron S.
Barlow, Sarah E.
Rao, Goutham
Inge, Thomas H.
Hayman, Laura L.
Steinberger, Julia
Urbina, Elaine M.
Ewing, Linda J.
Daniels, Stephen R.
机构
关键词
AHA Scientific Statements; adolescents; children; obesity; risk factors; BODY-MASS INDEX; FATTY LIVER-DISEASE; LAPAROSCOPIC SLEEVE GASTRECTOMY; TYPE-2; DIABETES-MELLITUS; INTIMA-MEDIA THICKNESS; C-REACTIVE PROTEIN; Y GASTRIC BYPASS; QUALITY-OF-LIFE; FAMILY-BASED TREATMENT; CONTROLLED-RELEASE PHENTERMINE/TOPIRAMATE;
D O I
10.1161/CIR.0b013e3182a5cfb3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Severe obesity afflicts between 4% and 6% of all youth in the United States, and the prevalence is increasing. Despite the serious immediate and long-term cardiovascular, metabolic, and other health consequences of severe pediatric obesity, current treatments are limited in effectiveness and lack widespread availability. Lifestyle modification/behavior-based treatment interventions in youth with severe obesity have demonstrated modest improvement in body mass index status, but participants have generally remained severely obese and often regained weight after the conclusion of the treatment programs. The role of medical management is minimal, because only 1 medication is currently approved for the treatment of obesity in adolescents. Bariatric surgery has generally been effective in reducing body mass index and improving cardiovascular and metabolic risk factors; however, reports of long-term outcomes are few, many youth with severe obesity do not qualify for surgery, and access is limited by lack of insurance coverage. To begin to address these challenges, the purposes of this scientific statement are to (1) provide justification for and recommend a standardized definition of severe obesity in children and adolescents; (2) raise awareness of this serious and growing problem by summarizing the current literature in this area in terms of the epidemiology and trends, associated health risks (immediate and long-term), and challenges and shortcomings of currently available treatment options; and (3) highlight areas in need of future research. Innovative behavior-based treatment, minimally invasive procedures, and medications currently under development all need to be evaluated for their efficacy and safety in this group of patients with high medical and psychosocial risks.
引用
收藏
页码:1689 / 1712
页数:24
相关论文
共 270 条
[61]   Relationship of childhood obesity to coronary heart disease risk factors in adulthood: The Bogalusa Heart Study [J].
Freedman, DS ;
Khan, LK ;
Dietz, WH ;
Srinivasan, SR ;
Berenson, GS .
PEDIATRICS, 2001, 108 (03) :712-718
[62]   The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes [J].
Freemark, M ;
Bursey, D .
PEDIATRICS, 2001, 107 (04) :E55
[63]   Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention [J].
Fu, J-F ;
Liang, L. ;
Zou, C-C ;
Hong, F. ;
Wang, C-L ;
Wang, X-M ;
Zhao, Z-Y .
INTERNATIONAL JOURNAL OF OBESITY, 2007, 31 (01) :15-22
[64]   Tracking of body mass index during childhood: a 15-year prospective population-based family study in eastern Finland [J].
Fuentes, RM ;
Notkola, IL ;
Shemeikka, S ;
Tuomilehto, J ;
Nissinen, A .
INTERNATIONAL JOURNAL OF OBESITY, 2003, 27 (06) :716-721
[65]   Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial [J].
Gadde, Kishore M. ;
Allison, David B. ;
Ryan, Donna H. ;
Peterson, Craig A. ;
Troupin, Barbara ;
Schwiers, Michael L. ;
Day, Wesley W. .
LANCET, 2011, 377 (9774) :1341-1352
[66]   Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine [J].
Gardin, JM ;
Schumacher, D ;
Constantine, G ;
Davis, KD ;
Leung, C ;
Reid, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1703-1709
[67]   Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study [J].
Garvey, W. Timothy ;
Ryan, Donna H. ;
Look, Michelle ;
Gadde, Kishore M. ;
Allison, David B. ;
Peterson, Craig A. ;
Schwiers, Michael ;
Day, Wesley W. ;
Bowden, Charles H. .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2012, 95 (02) :297-308
[68]  
Gidding SS, 2004, J PEDIATR-US, V144, P766, DOI 10.1016/S0022-3476(04)00243-4
[69]   SNORING, APNEIC EPISODES, AND NOCTURNAL HYPOXEMIA AMONG CHILDREN 6 MONTHS TO 6 YEARS OLD - AN EPIDEMIOLOGIC-STUDY OF LOWER LIMIT OF PREVALENCE [J].
GISLASON, T ;
BENEDIKTSDOTTIR, B .
CHEST, 1995, 107 (04) :963-966
[70]   Depressive Symptoms in Severely Obese Compared With Normal Weight Adolescents: Results From a Community-Based Longitudinal Study [J].
Goodman, Elizabeth ;
Must, Aviva .
JOURNAL OF ADOLESCENT HEALTH, 2011, 49 (01) :64-69